CDT Equity (CDT) Competitors $0.70 0.00 (-0.31%) Closing price 04:00 PM EasternExtended Trading$0.70 0.00 (-0.68%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. KPRX, APRE, CSCI, ENTO, EVOK, BMRA, SNPX, PRTG, CYCN, and OBSVShould you be buying CDT Equity stock or one of its competitors? The main competitors of CDT Equity include Kiora Pharmaceuticals (KPRX), Aprea Therapeutics (APRE), COSCIENS Biopharma (CSCI), Entero Therapeutics (ENTO), Evoke Pharma (EVOK), Biomerica (BMRA), Synaptogenix (SNPX), Portage Biotech (PRTG), Cyclerion Therapeutics (CYCN), and ObsEva (OBSV). These companies are all part of the "pharmaceutical products" industry. CDT Equity vs. Its Competitors Kiora Pharmaceuticals Aprea Therapeutics COSCIENS Biopharma Entero Therapeutics Evoke Pharma Biomerica Synaptogenix Portage Biotech Cyclerion Therapeutics ObsEva Kiora Pharmaceuticals (NASDAQ:KPRX) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Which has preferable valuation and earnings, KPRX or CDT? Kiora Pharmaceuticals has higher revenue and earnings than CDT Equity. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.55$3.60M-$2.91-0.88CDT EquityN/AN/A-$17.80M-$435.000.00 Is KPRX or CDT more profitable? CDT Equity's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -47.17% -34.00% CDT Equity N/A N/A -350.23% Do institutionals and insiders have more ownership in KPRX or CDT? 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 7.7% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, KPRX or CDT? Kiora Pharmaceuticals has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Do analysts recommend KPRX or CDT? Kiora Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 289.11%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Kiora Pharmaceuticals is more favorable than CDT Equity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50CDT Equity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer KPRX or CDT? In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 1 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 1.91 equaled CDT Equity'saverage media sentiment score. Company Overall Sentiment Kiora Pharmaceuticals Very Positive CDT Equity Very Positive SummaryKiora Pharmaceuticals beats CDT Equity on 8 of the 12 factors compared between the two stocks. Get CDT Equity News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricCDT EquityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.15M$2.49B$5.65B$10.30BDividend YieldN/A56.32%5.68%4.62%P/E Ratio0.0023.2775.8426.11Price / SalesN/A578.02517.39171.57Price / CashN/A174.1537.5661.52Price / Book-0.015.1412.876.30Net Income-$17.80M$32.95M$3.29B$271.03M7 Day Performance2.40%0.10%-0.26%-0.14%1 Month Performance-59.38%5.05%3.85%6.42%1 Year Performance-99.63%1.04%68.36%28.81% CDT Equity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTCDT Equity0.7898 of 5 stars$0.70-0.3%N/A-99.6%$2.15MN/A0.003Positive NewsGap DownKPRXKiora Pharmaceuticals2.9533 of 5 stars$2.61+3.2%$10.00+283.1%-23.5%$8.69M$16.02M-0.9010Positive NewsAPREAprea Therapeutics2.8135 of 5 stars$1.47+2.1%$15.50+954.4%-52.3%$8.39M$1.50M-0.637CSCICOSCIENS BiopharmaN/A$2.61-15.3%N/A-29.8%$8.29M$9.44M-0.4320Gap DownHigh Trading VolumeENTOEntero TherapeuticsN/A$4.99-3.3%N/A+428.3%$8.20MN/A0.009News CoverageGap DownEVOKEvoke Pharma0.15 of 5 stars$5.12-1.9%N/A+1.2%$8.14M$10.25M-2.004BMRABiomerica0.7707 of 5 stars$2.84-1.4%N/A+7.0%$8.11M$5.31M-1.2260SNPXSynaptogenixN/A$5.83-7.0%N/A+84.1%$8.10MN/A-0.584PRTGPortage BiotechN/A$7.63+9.6%N/A+11.7%$8.01MN/A-0.186Gap UpHigh Trading VolumeCYCNCyclerion Therapeutics1.4613 of 5 stars$3.04+27.7%N/A+14.8%$7.94M$2M-4.1130News CoverageHigh Trading VolumeOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050 Related Companies and Tools Related Companies Kiora Pharmaceuticals Alternatives Aprea Therapeutics Alternatives COSCIENS Biopharma Alternatives Entero Therapeutics Alternatives Evoke Pharma Alternatives Biomerica Alternatives Synaptogenix Alternatives Portage Biotech Alternatives Cyclerion Therapeutics Alternatives ObsEva Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CDT Equity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CDT Equity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDT Stock Alerts